Donald Ingber
Fondateur chez Emulate, Inc.
Profil
Donald Ingber is the founder of Emulate, Inc. and Unravel Biosciences, Inc. He currently holds the position of Director & Head-Scientific Advisory Board at BOA Biomedical, Inc. He completed his undergraduate, graduate, and doctorate degrees at Yale University.
Postes actifs de Donald Ingber
| Sociétés | Poste | Début |
|---|---|---|
Emulate, Inc.
 Emulate, Inc. Drugstore ChainsRetail Trade Emulate, Inc. owns and operates Organs-on-Chips platform which acts as an automated human bioemulation platform for mimicking true human physiology. The firm's product responses to medicines, chemicals, and diseases can be predicted. The company was founded by James Coon, Donald Ingber and Geraldine Hamilton in July 2014 and is headquartered in Cambridge, MA. | Fondateur | - |
BOA Biomedical, Inc.
 BOA Biomedical, Inc. Medical SpecialtiesHealth Technology BOA Biomedical, Inc. is a Miraki innovation company that focuses on infectious disease. The private company is based in Cambridge, MA. The company's mission is to provide innovative tools to fight the world's most deadly infectious diseases and their outcomes, including sepsis, hospital-acquired infections, antibiotic resistance, pandemic infections, pathogenic outbreaks, and the threat of bioterrorism. BOA Biomedical has an exclusive license to technology from the Wyss Institute. The company's platform manages infectious disease throughout the patient journey from diagnosis to tracking to treatment. The company was founded by Christopher J. P. Velis. | Directeur/Membre du Conseil | - |
Unravel Biosciences, Inc.
 Unravel Biosciences, Inc. BiotechnologyHealth Technology Unravel Biosciences is a rapid prototyping therapeutics company that uses AI biological network analysis and existing drugs to discover and clinically derisk entirely novel therapeutics and biomarkers for complex diseases. Unravel Biosciences is based in Boston, MA and was founded by Richard Novak, Frederic Vigneault, Michael Levin, and Donald Ingber. The company leverages its proprietary Bionav™ platform to combine target and drug discovery, preclinical screening, and patient stratification. Richard Novak has been the CEO since incorporation. | Fondateur | - |
Formation de Donald Ingber
| Yale University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Emulate, Inc.
Emulate, Inc. Drugstore ChainsRetail Trade Emulate, Inc. owns and operates Organs-on-Chips platform which acts as an automated human bioemulation platform for mimicking true human physiology. The firm's product responses to medicines, chemicals, and diseases can be predicted. The company was founded by James Coon, Donald Ingber and Geraldine Hamilton in July 2014 and is headquartered in Cambridge, MA. | Retail Trade |
BOA Biomedical, Inc.
BOA Biomedical, Inc. Medical SpecialtiesHealth Technology BOA Biomedical, Inc. is a Miraki innovation company that focuses on infectious disease. The private company is based in Cambridge, MA. The company's mission is to provide innovative tools to fight the world's most deadly infectious diseases and their outcomes, including sepsis, hospital-acquired infections, antibiotic resistance, pandemic infections, pathogenic outbreaks, and the threat of bioterrorism. BOA Biomedical has an exclusive license to technology from the Wyss Institute. The company's platform manages infectious disease throughout the patient journey from diagnosis to tracking to treatment. The company was founded by Christopher J. P. Velis. | Health Technology |
Unravel Biosciences, Inc.
Unravel Biosciences, Inc. BiotechnologyHealth Technology Unravel Biosciences is a rapid prototyping therapeutics company that uses AI biological network analysis and existing drugs to discover and clinically derisk entirely novel therapeutics and biomarkers for complex diseases. Unravel Biosciences is based in Boston, MA and was founded by Richard Novak, Frederic Vigneault, Michael Levin, and Donald Ingber. The company leverages its proprietary Bionav™ platform to combine target and drug discovery, preclinical screening, and patient stratification. Richard Novak has been the CEO since incorporation. | Health Technology |
